Resting State Electroencephalogram for Psychotic Disorders

November 18, 2022 updated by: Renrong Wu, Central South University

Self-control, Appetite and Psychotic Diagnose: a Resting State EEG Cross Section Study

Electroencephalography (EEG) has been proposed as a neurophysiological biomarker to delineate psychotic disorders. Meanwhile, the increased appetite, which might related to self-control process, has been an increasing concern for the management of psychotic disorders. In this cross-section study, investigators collect the resting state EEG data, self-control related scale, eating behaviour questionnaire and psychotic syndrome related assessement and try to find the connection between those measurers, in order to provide novel understanding on the mechanism of psychotic diseases.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

201

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Hunan
      • Changsha, Hunan, China, 410011
        • Mental Health Institute of 2nd Xiangya Hospital,CSU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants were recuited for single center, second xiangya hospital psychiatry department. Both inpatients and outpatients were recuited.

Description

Inclusion Criteria:

Diagnosed with schizophrenia or bipolar disorder or MDD in accordance with DMS-5 Informed Consent

Exclusion Criteria:

Diagnosed with other mental disease in accordance with DSM-5 Comorbid with other severe physiological disease Drug or alcohol abuse Pregnant or lactating

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Schizophrenia patients
patients who diagnosed with schizophrenia in accordance with DSM-5 criteria
Other: No intervention
No intervention
Bipolar disorder patients
patients who diagnosed with bipolar disorder in accordance with DSM-5 criteria
Other: No intervention
No intervention
Depression patients
patients who diagnosed with major depression disorder in accordance with DSM-5 criteria
Other: No intervention
No intervention
Health control
health participants who have not diagnosed with any psychological or psychiatric disease.
Other: No intervention
No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
resting state EEG
Time Frame: baseline
resting state electroencephalography
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Three factor eating questionnaire
Time Frame: baseline
min value 21, max value 84. The higher scores mean more unhealthy eating behavior.
baseline
Barratt Impulsivity Scale
Time Frame: baseline
min score 26, max score 104. The higher score means more impulsive.
baseline
Self-Control Scale
Time Frame: baseline
min score 36, max score 180. The higher score means less self control.
baseline
The positive and negative syndrome scale
Time Frame: baseline
min score 30, max score 210. The higher score means more severe symptoms.
baseline
Hamilton anxiety rating scale
Time Frame: baseline
min score 14, max score 56. The higher score means more severe anxiety symptom
baseline
Hamilton depression rating scale
Time Frame: baseline
min score 17, max score 68. The higher score means more severe depressive symptom
baseline
Young manic rating scale
Time Frame: baseline
min score 0, max score 60, the higher score means more severe manic syndrome.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Central South University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 1, 2021

Primary Completion (ANTICIPATED)

June 1, 2023

Study Completion (ANTICIPATED)

December 1, 2023

Study Registration Dates

First Submitted

September 23, 2021

First Submitted That Met QC Criteria

September 23, 2021

First Posted (ACTUAL)

October 4, 2021

Study Record Updates

Last Update Posted (ACTUAL)

November 21, 2022

Last Update Submitted That Met QC Criteria

November 18, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WU2021EEG

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe